To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers
Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :
It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).
Researchers from SIMoS and SPI (DMTS) demonstrate that molecular engineering of llama antibodies, capable of neutralizing SARS-CoV-1, allows to obtain optimized antibodies with very high affinities for SARS-CoV-2 and its variants, the culprits of the Covid-19 epidemic.
A team from SIMoS, in collaboration with the SCBM (DMTS), has developed an original bioanalytical approach based on the double 14C-3H isotopic labeling of an antibody-drug conjugate, allowing the simultaneous in vivo monitoring of the two components in mouse models as well as their precise quantification in the organs.
Researchers at the LERI together with the AP-HP have developed 2 rapid and inexpensive immunological tests to detect antibiotic resistance. The novelty: the tests detect the activity of bacterial enzymes that hydrolyze extended-spectrum cephalosporins.
SIMoS team, in collaboration with Bicêtre Hospital, shows that certolizumab pegol, a pegylated monoclonal antibody fragment for anti-inflammatory use, is less likely to trigger an adverse immune response than the non-pegylated form.
A team from SPI used mass spectrometry to analyze the degree of alteration of the intestinal microbiota of Covid-19 patients and to look for signatures of intestinal infection by the SARS-CoV-2 virus. The level of the observed gut dysbiosis would be an indicator of the stage and extent of the infection.
The ptairMS software, developed in the framework of a collaboration led by the CEA-Joliot, allows the processing and analysis of proton transfer mass spectrometry data, an ideal method for the real-time study of volatile organic compounds (VOCs) present in exhaled breath.
Researchers at the LIAA (SPI/DMTS) show that the initial route of sensitization to a food allergen (oral, respiratory, cutaneous) directly influences the nature of immune responses at multiple sites in the body.
To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified
IBiSA, within the Frédéric Joliot Institute for Life Sciences:
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.